MX2008016210A - Proteinas capside virales y algunos peptidos o composiciones de las mismas para el tratamiento de trastornos patologicos. - Google Patents

Proteinas capside virales y algunos peptidos o composiciones de las mismas para el tratamiento de trastornos patologicos.

Info

Publication number
MX2008016210A
MX2008016210A MX2008016210A MX2008016210A MX2008016210A MX 2008016210 A MX2008016210 A MX 2008016210A MX 2008016210 A MX2008016210 A MX 2008016210A MX 2008016210 A MX2008016210 A MX 2008016210A MX 2008016210 A MX2008016210 A MX 2008016210A
Authority
MX
Mexico
Prior art keywords
treatment
capsid proteins
compositions
viral capsid
disorders
Prior art date
Application number
MX2008016210A
Other languages
English (en)
Inventor
Ariella Oppenheim
Original Assignee
G V T Gene Vector Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G V T Gene Vector Technologies filed Critical G V T Gene Vector Technologies
Publication of MX2008016210A publication Critical patent/MX2008016210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a proteínas cápside virales, como un medicamento para el tratamiento de un trastorno patológico. Más particularmente, la invención se refiere a las proteínas cápside virales VP1, VP2 y VP3, preferiblemente, la VP1 de SV4O o cualquier péptido, fragmento, mutante, derivado y mezclas de la misma, o de partículas de tipo virus (VLPs) que comprenden las mismas, como el ingrediente activo en composiciones para el tratamiento de trastornos patológicos, preferiblemente trastornos asociados con la desactivación de proteínas celulares involucradas con procesos de control de calidad, particularmente, chaperonas. La invención además proporciona métodos para el tratamiento de tales trastornos y el uso de las proteínas cápside de SV4O para la preparación de composiciones farmacéuticas.
MX2008016210A 2006-06-18 2007-06-18 Proteinas capside virales y algunos peptidos o composiciones de las mismas para el tratamiento de trastornos patologicos. MX2008016210A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL176377A IL176377A0 (en) 2006-06-18 2006-06-18 Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders
PCT/IL2007/000735 WO2007148326A2 (en) 2006-06-18 2007-06-18 Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders

Publications (1)

Publication Number Publication Date
MX2008016210A true MX2008016210A (es) 2009-10-28

Family

ID=38833854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008016210A MX2008016210A (es) 2006-06-18 2007-06-18 Proteinas capside virales y algunos peptidos o composiciones de las mismas para el tratamiento de trastornos patologicos.

Country Status (9)

Country Link
US (3) US7803761B2 (es)
EP (1) EP2029176B1 (es)
JP (1) JP2009541218A (es)
CN (1) CN101506357A (es)
AU (1) AU2007262376A1 (es)
CA (1) CA2655763A1 (es)
IL (2) IL176377A0 (es)
MX (1) MX2008016210A (es)
WO (1) WO2007148326A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL176377A0 (en) * 2006-06-18 2006-10-05 Ariella Oppenheim Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders
EP2926831A1 (en) 2014-03-31 2015-10-07 Ruprecht-Karls-Universität Heidelberg CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination
KR20210005624A (ko) * 2018-04-23 2021-01-14 게자 에이디 리미티드 캡시드 단위로 캡슐화된 핵산 오리가미 구조

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109558A (en) * 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
IL115880A (en) * 1995-11-06 2008-11-26 Hadasit Med Res Service Construct for infecting mammalian cells comprising the sv40 vp1 capsid protein and a histone - free constituent, methods of construction and uses thereof
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DE19750220A1 (de) * 1997-11-13 1999-05-20 Max Delbrueck Centrum Verfahren zur Gewinnung von virusähnlichen Partikeln auf der Basis von Polyomaviren
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
AU2002211490A1 (en) 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
IL164850A0 (en) * 2004-10-26 2005-12-18 Yissum Res Dev Co Gene therapy for kidney diseases
IL176377A0 (en) 2006-06-18 2006-10-05 Ariella Oppenheim Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders

Also Published As

Publication number Publication date
AU2007262376A2 (en) 2009-02-19
JP2009541218A (ja) 2009-11-26
WO2007148326A3 (en) 2009-04-30
EP2029176B1 (en) 2014-02-19
US20100284974A1 (en) 2010-11-11
CA2655763A1 (en) 2007-12-27
US8637447B2 (en) 2014-01-28
EP2029176A4 (en) 2011-04-13
CN101506357A (zh) 2009-08-12
IL195901A0 (en) 2009-09-01
US20100261655A1 (en) 2010-10-14
US7803761B2 (en) 2010-09-28
US8158576B2 (en) 2012-04-17
WO2007148326A2 (en) 2007-12-27
US20090209467A1 (en) 2009-08-20
IL176377A0 (en) 2006-10-05
EP2029176A2 (en) 2009-03-04
AU2007262376A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
PH12020550706A1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
PH12018502387A1 (en) Adeno-associated virus variant capsids and methods of use thereof
HK1071518A1 (en) Improved raav expression systems for genetic modification of specific capsid proteins
MXPA05008617A (es) Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i.
US8614082B2 (en) Attenuation of encephalitogenic alphavirus and uses thereof
UA98776C2 (ru) СПОСОБ ДОСТАВКИ лекарственного ПРЕПАРАТА ДЛЯ УСИЛЕНИЯ СИНТЕЗА БЕЛКА В КОСТЯХ
TW200605909A (en) Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
MA27699A1 (fr) Vaccin contre vhc
WO2016109649A1 (en) Methods and compositions for treating brain diseases
MX2008016210A (es) Proteinas capside virales y algunos peptidos o composiciones de las mismas para el tratamiento de trastornos patologicos.
TN2012000431A1 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
Wen et al. Multifunctionality of structural proteins in the enterovirus life cycle
CA3149041A1 (en) Compositions and methods for treating viral infections
TNSN07166A1 (en) Composition comprising vlp and amyloid-beta peptide
JP2009541218A5 (es)
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
US20210238232A1 (en) Compositions and methods for treating viral infections
US20220282279A1 (en) Compositions and methods for treating and preventing coronavirus infections
MY186651A (en) Adeno-associated virus variant capsids and methods of use thereof
Takahashi et al. Oligonucleotide Therapeutics PK-7010 in Combination with Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice
CA2971687C (en) Methods and compositions for treating brain diseases
Hamann et al. Intermittent human parathyroid hormone (1-84) treatment improves bone mass and bone defect healing in rats with type 2 diabetes mellitus
NZ733014A (en) Methods and compositions for treating brain diseases

Legal Events

Date Code Title Description
FG Grant or registration